Literature DB >> 6885970

Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin.

M J Welch, E R Stiehm.   

Abstract

A 35-year-old man with common variable hypogammaglobulinemia had repeated anaphylactic reactions to intramuscular human immune serum globulin (HISG), preventing him from receiving the injections. He was able to tolerate slow subcutaneous HISG infusions without local or systemic side effects at a dose of 12 ml/week given at a rate of 2 ml/hr. He has been maintained on these infusions for 2 years in an infection-free state.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6885970     DOI： 10.1007/bf00915353

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


  5 in total

1.  Alleged anaphylactic reactions to human gamma-globulin.

Authors:  J GLASER; W A WYSS-SOUFFRONT
Journal:  Pediatrics       Date:  1961-09       Impact factor: 7.124

Review 2.  Standard and special human immune serum globulins as therapeutic agents.

Authors:  E R Stiehm
Journal:  Pediatrics       Date:  1979-02       Impact factor: 7.124

3.  Adverse reactions following administration of human gamma globulin.

Authors:  E F Ellis; C S Henney
Journal:  J Allergy       Date:  1969-01

4.  Anaphylactoid reaction to human gamma globulin. Report of a case and inquiry into mechanism.

Authors:  H B Richerson; P M Seebohm
Journal:  Arch Intern Med       Date:  1966-04

5.  Immunoglobulin replacement therapy by slow subcutaneous infusion.

Authors:  M Berger; T R Cupps; A S Fauci
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391
  5 in total
  6 in total

Review 1.  Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.

Authors:  S Jolles; J S Orange; A Gardulf; M R Stein; R Shapiro; M Borte; M Berger
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

2.  Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens.

Authors:  Akhilesh Chouksey; Kimberly Duff; Nancy Wasserbauer; Melvin Berger
Journal:  Allergy Asthma Clin Immunol       Date:  2005-09-15       Impact factor: 3.406

3.  Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.

Authors:  John B Hagan; Mary B Fasano; Sheldon Spector; Richard L Wasserman; Isaac Melamed; Mikhail A Rojavin; Othmar Zenker; Jordan S Orange
Journal:  J Clin Immunol       Date:  2010-05-08       Impact factor: 8.317

4.  Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.

Authors:  Michael C Runken; Joshua M Noone; Christopher M Blanchette; Emily Zacherle; Reuben Howden
Journal:  Am Health Drug Benefits       Date:  2019-10

5.  Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.

Authors:  Lisa Kobrynski
Journal:  Biologics       Date:  2012-08-24

Review 6.  Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency.

Authors:  Melvin Berger
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.